BMS 911543

Drug Profile

BMS 911543

Alternative Names: BMS-911543

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myelofibrosis

Most Recent Events

  • 09 Oct 2017 Discontinued - Phase-I/II for Myelofibrosis (Second-line therapy or greater) in Australia and USA (PO) before October 2017, because not listed on Bristol-Myers Squibb pipeline
  • 15 Dec 2016 Biomarkers information updated
  • 01 Nov 2015 Bristol-Myers Squibb completes a phase I/II trial in Myelofibrosis (Second-line therapy or greater) in USA and Australia (PO) (NCT01236352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top